Aligos Discontinues ALG-020572 in the (ALG-020572-401) Study for the Treatment of Chronic Hepatitis B
Shots:
- The company has decided to discontinue the development of ALG-020572 for patients with CHB
- The discontinuation was based on the 1st cohort of the (ALG-020572-401) study which showed that patients experienced a serious AEs with a significant increase in ALT, following the multiple dosing of ALG-020572 that resulted in hospitalization
- The funds will be redirected to support ongoing clinical programs including ALG-000184 (Class-II CAM) for CHB, ALG-055009 (THR- agonist) for NASH & accelerate internal small molecule development programs including a SARS-CoV-2 protease inhibitor, Class-I CAM for CHB & PD-L1 inhibitor for CHB
Ref: Aligos | Image: Aligos
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
